Thalidomide
You would like to know more about the topic of Thalidomide? Then make use of this link
History
The Development – Grünenthal Group
| 1946 | Hermann Wirtz founded Chemie Grünenthal GmbH |
| 1947 | Registration of Penicillin |
| 1957 | Launch of Thalidomide (withdrawn from market in 1961) |
| 1968 | First international activities |
| 1977 | Tramal® launched – worldwide partnering |
| 1979 | Expansion of the Latin America business through founding of subsidiaries in Columbia and Chile |
| Since 1990 | Increasing internationalization of Grünenthal through local founding of subsidiaries and aquisitions |
| since 2000 | Global launches (Zaldiar®, Transtec®) |
| since 2004 | Broad investments in R&D and late clinical trials |
| 2008 | Approval of Tapentadol in the US |
| 2009 | EU submission of Tapentadol for acute and chronic pain, launch of Nucynta® in the US by Johnson & Johnson |
| 2010 | Marketing authorization of Tapentadol IR and PR in 26 EU countries |
| 2011 | Market introduction in the United States of INTAC®, an innovative formulation technology for the protection of intended drug action. |
| 2011 | FDA approval and launch of Tapentadol ER for chronic pain. |
| 2012 | Palexia® is available in UK, Spain, Italy, Denmark, Sweden, Ireland, Portugal, Norway, Belgium and Switzerland. |
